Robert Froman Williamson
Independent DirectorMr. Robert Froman Williamson, III, MBA, also known as Rob, is Independent Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He served as Chief Business and Financial Officer at OncoMyx Therapeutics, Inc. since February 2022 until September, 2022. Mr. Williamson has experience in building, financing and leading private and public biotechnology companies through critical phases of growth. He served as President and Chief Executive Officer at BioTheryX, Inc. since 2020 and January 2021 until July 2021 and served as its Director until July 2021. He served as the Chief Executive Officer at PharmAkea Inc from 2013 until 2019 and ATXCo, oncology and fibrosis drug development companies financed through a partnership with Celgene, through PharmAkea's acquisition by Galecto and ATXCo's acquisition by Blade Therapeutics. Mr. Williamson is involved in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers. He served as an Acting Chief Executive Officer of BrainCells Inc. and Executive Chairman of privately held Strategic Enzyme Applications, Inc. and founded it Mr. Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology (acquired by Protein Design Labs) and Chief Operating Officer of DoubleTwist (acquired in part by Merck and Hitachi). He served as Chief Executive Officer of Arriva Pharmaceuticals, Inc. since September 2004. He served as President and Chief Operating Officer of Eos Biotechnology, Inc. He served as Chief Operating Officer of DoubleTwist, Inc. (formerly, Pangea) since December 1999. Before managing life sciences companies, Currently, Mr. Williamson serves as Chairman of HAYA Therapeutics SA and as a member of the Board of Directors of the Coulter Center in Miami. Mr. Williamson was a partner with The Boston Consulting Group, Inc. and a research assistant for the Federal Reserve Board and his clients included pharmaceutical, medical device and health care companies with additional clients in high technology and energy. Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, D.C. He served as Director of Presidio Pharmaceuticals, Inc. PharmAkea, Inc. and Arriva Pharmaceuticals, Inc. He served as Director of Pharmasset, Inc. from August 2004 to January 17, 2012 and Progen Pharmaceuticals Limited from March 04, 2008 to March 27, 2009. Mr. Williamson received a B.A. in Economics from Pomona College and an M.B.A. from Stanford Graduate School of Business and Stanford University. He is President of Triumvira Immunologics Inc. from 2022 and served as its CBO until 2023 and in March, 2022, has served as a senior adviser to SyntheX, a protein interaction and degrader company. He also served as COO and Director of Triumvira Immunologics Inc. since July 2023. Mr. Williamson also serves on the Coulter Oversight Board for University of Miami, Florida, is a qualified financial expert.
Positions
- Company NamePerspective Therapeutics, Inc.Stock CodeCATXPositionIndependent DirectorColleagues
- JMJohan M. SpoorCEO & Director
- LALori A. Holmes-WoodsChairperson of the Board
- JDJoel David SendekCFO & Principal Financial Officer
- MPMarkus PuhlmannChief Medical Officer
- MKMichael K. SchultzCo-Founder & Senior Scientific Advisor
- SCShane CobbExecutive Vice President of Operations
- FMFrank MorichIndependent Director
- HHHeidi HensonIndependent Director
